Latest stories

  • in

    Glenmark Gets CDSCO panel nod for Phase IV CT of COPD drug

    New Delhi: Pharmaceutical major, Glenmark has got the green signal from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) to conduct the Phase IV clinical trial of the fixed dose combination (FDC) Glycopyrrolate plus Budesonide plus Formoterol Fumarate dihydrate actuation delivers inhalation aerosol. However, this approval is subjected to […] More

  • in

    Glenmark Pharma weighs selling stake in Glenmark Lifesciences

    Glenmark Pharma weighs selling stake in Glenmark Lifesciences

    Bengaluru: India’s Glenmark Pharmaceuticals Ltd is considering selling a majority of the 82% stake it holds in Glenmark Life Sciences Ltd as it looks to lower its debt load, the Mint business daily reported on Tuesday. Glenmark Pharma has hired Kotak Mahindra Capital Co Ltd to oversee the sale of its stake in Glenmark Life and […] More

  • in

    Glenmark gets CDSCO panel nod to manufacture ,market pulmonary FDC drug

    Glenmark gets CDSCO panel nod to manufacture ,market pulmonary FDC drug

    New Delhi: The drug major Glenmark has got the go ahead from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organization (CDSCO) to manufacture and market a fixed dose combination pulmonary drug, which each capsule contains Indacaterol (as acetate) equivalent to Indacaterol 150 mcg, Glycopyrrolate IP equivalent to glycopyrronium 50 mcg, […] More